Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Calcipotriol as Radioprotector of Skin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Rabin Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00445250
First received: March 7, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted

March 7, 2007
March 7, 2007
Not Provided
Not Provided
Prevention of radiodermatitis
Same as current
No Changes Posted
Side effects of Calcipotriol
Same as current
Not Provided
Not Provided
 
The Role of Calcipotriol as Radioprotector of Skin
Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.

Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast.

To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.

STUDY PROTOCOL

Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria:

  1. . an assessment by a physician and a nurse according to the RTOG score (6).

    As follows:

    Grade 0 – no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 – extensive moist peeling, pitting edema. Grade 4 – ulcers, bleeding and necrosis.

  2. . A questionnaire to each patient regarding the efficacy and safety of the cream.
  3. . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment.

Safety report will be sent to the local independent ethics committee after the examination of the first ten patients.

The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated.

INCLUSION CRITERIA

  1. . Age ranging from 18 to 75.
  2. . Confirmed histological diagnosis of Breast cancer.
  3. . Radiotherapy treatment to the breast following lumpectomy.

EXCLUSION CRITERIA

  1. . Scleroderma.
  2. . An extremely large breast. Interfiled above 25 cm.
  3. . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. . Mastectomy.
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Radiodermatitis
Drug: Calcipotriol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
50
Not Provided
Not Provided

Inclusion Criteria:

  1. Age ranging from 18 to 75.
  2. Confirmed histological diagnosis of Breast cancer.
  3. Radiotherapy treatment to the breast following lumpectomy.

Exclusion Criteria:

  1. Scleroderma.
  2. An extremely large breast. Interfiled above 25 cm.
  3. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. Mastectomy.
Female
18 Years to 75 Years
No
Contact: Eyal Fenig, M.D. 97239377964 efenig@clalit.org.il
Contact: Ofer Purim, M.D. 97239377973 oferp@clalit.org.il
Israel
 
NCT00445250
004253
Yes
Not Provided
Rabin Medical Center
Not Provided
Principal Investigator: Eyal Fenig, M.D. Rabin Medical Center
Rabin Medical Center
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP